Cell death discovery
Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.
Silvia Sabbioni, Paola Guerriero, Ram C Shankaraiah, Laura Masatti, Angelo Michilli, Cristian Bassi, Lucilla D'Abundo, Farzaneh Moshiri, Bruno De Siena, Edi Simoni, Laura Astolfi, Laura Gramantieri, Roberta Roncarati, Bahaeldin K Elamin, Massimo Bonora
Published: 202610.1038/s41420-026-02940-3
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of cancer-related death worldwide. The prognosis is poor, with a median survival of 12-15 months in patients with advanced-stage disease. Early diagnosis and…
Preview only. Read the full abstract at the source